Takashi Seto

16PUBLICATIONS
58CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)AllergyRadiation therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Sep 01, 2023
Five-Year Overall Survival Analysis of the JIPANG Study: Pemetrexed or Vinorelbine Plus Cisplatin for Resected Stage II-IIIA Nonsquamous Non-Small-Cell Lung Cancer.

Hirotsugu Kenmotsu, Nobuyuki Yamamoto, Toshihiro Misumi

|Mar 06, 2023
TRUST-II: a global phase II study of taletrectinib in ROS1-positive non-small-cell lung cancer and other solid tumors.

Misako Nagasaka, Yuichiro Ohe, Caicun Zhou

|Jul 23, 2022
Phase II study of S-1 plus cisplatin with concurrent radiotherapy for locally advanced thymic carcinoma: Results of the LOGIK1605/JART-1501 study.

Minoru Fukuda, Masafumi Yamaguchi, Takuya Yamazaki

|Feb 11, 2022
Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors.

George D Demetri, Filippo De Braud, Alexander Drilon

|Feb 02, 2022
Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study).

Takashi Seto, Kaname Nosaki, Mototsugu Shimokawa

|Oct 24, 2021
Successful treatment of locally advanced lung cancer using late concurrent chemoradiation therapy administered after immune checkpoint inhibitor plus platinum chemotherapy.

Taichi Matsubara, Shinkichi Takamori, Takatoshi Fujishita

Pageof 3

Frequent Collaborators

5 joint publications

Shinkichi Takamori

2 joint publications

Makoto Nishio

2 joint publications

Kenji Sugio

2 joint publications

Nobuyuki Yamamoto